Bexagliflozin vs Dapagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos and partners
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)
Result source: NCT02769481
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)
Result source: NCT01392677
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bexagliflozin | Dapagliflozin |
|---|---|---|
| HbA1c, change | -0.8% vs -0.4%−0.5 vs placeboNCT0255829623 other results
| -0.9% vs -0.2%−0.7 vs placeboNCT0052837250 other results
|
| Body weight, change (kg) | -3.0 vs -0.4−2.6 vs placeboNCT0255829614 other results
| -3.2 vs -2.2−1 vs placeboNCT0052837240 other results
|
| HbA1c below 7% | —Not reported | 50.8% vs 31.6%+19.2 vs placeboNCT0052837217 other results
|
| Fasting plasma glucose, change | -2.5 vs -1.2−1.3 vs placeboNCT0325978910 other results
| -1.3 vs 0.2−1.5 vs placeboNCT0098486734 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT04170998 |
HbA1c, change
- Bexagliflozin
- -0.8% vs -0.4%−0.5 vs placeboNCT02558296
23 other results
- -1.1% vs -0.6% NCT03259789
- -0.5% vs -0.1% NCT02715258
- -0.6% vs -0.3% NCT02836873
- -0.7% vs -0.8% NCT03115112
- -0.7% vs -0.7% NCT02769481
- -1.1% vs -0.6% NCT03259789
- -0.6% vs -0.4% NCT02836873
- -0.6% vs -0.2% NCT02836873
- -1% vs -0.5% NCT03259789
- -1.0% vs -0.3% NCT03259789
- -0.7% vs -0.2% NCT03259789
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.3% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- Dapagliflozin
- -0.9% vs -0.2%−0.7 vs placeboNCT00528372
50 other results
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.2% NCT01392677
- -0.9% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.6% vs 0.1% NCT00357370
- -0.7% vs 0.1% NCT00357370
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.3% NCT00528879
- -0.8% vs -0.1% NCT00680745
- -1.0% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.8% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.5% vs 0.0% NCT00984867
- -0.6% vs 0.4% NCT03199053
- -1.2% vs -1.4% NCT00643851
- -2.0% vs -1.4% NCT00643851
- -2.0% vs -1.4% NCT00859898
- -1.4% vs -1.4% NCT00859898
- -0.5% vs -0.5% NCT00660907
- -0.9% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.7% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -2.0% vs 0.2% NCT00528372
- -1.2% vs 0.2% NCT00528372
- -1.4% vs -0.5% NCT00528879
- -0.8% vs 0.0% NCT00984867
- -2% vs 0.2% NCT00528372
- -1.5% vs 0.2% NCT00528372
- -1.3% vs 0.2% NCT00528372
- -1.4% vs 0.2% NCT00528372
- -1.3% vs -0.5% NCT00528879
- -1.2% vs -0.5% NCT00528879
- -1.7% vs -1.8% NCT00643851
- -3.0% vs -1.8% NCT00643851
- -2.6% vs -2.0% NCT00859898
- -2.1% vs -2.0% NCT00859898
- -1% vs -0.5% NCT02564926
Body weight, change (kg)
- Bexagliflozin
- -3.0 vs -0.4−2.6 vs placeboNCT02558296
14 other results
- -3.6 vs -1.1 NCT03259789
- -1.9 vs -1.1 NCT02715258
- -2.3 vs -0.6 NCT02836873
- -3.4 vs -0.8 NCT03115112
- -3.7 vs 0.6 NCT02769481
- -1.9 vs -0.1 NCT02390050
- -1.5 vs 0.0 NCT02390050
- -1.0 vs 0 NCT02390050
- -1.7 vs -0.1 NCT02390050
- -1.4 vs 0.0 NCT02390050
- -0.8 vs 0 NCT02390050
- -1.6 vs -0.1 NCT02390050
- -1 vs 0.0 NCT02390050
- -0.7 vs 0 NCT02390050
- Dapagliflozin
- -3.2 vs -2.2−1 vs placeboNCT00528372
40 other results
- -3.0 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -2.6 vs -0.6 NCT01392677
- -1.7 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -2.8 vs -2.2 NCT00528372
- -3.5 vs -2.2 NCT00528372
- -2.9 vs -2.4 NCT00528372
- -3.7 vs -2.4 NCT00528372
- -3.3 vs -2.2 NCT00528372
- -3.8 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -4.3 vs -2.4 NCT00528372
- -2.9 vs -0.9 NCT00528879
- -3.1 vs -1.0 NCT00528879
- -2.3 vs -0.7 NCT00680745
- -2.5 vs -0.8 NCT00680745
- -0.1 vs 1.6 NCT00683878
- -0.1 vs 1.8 NCT00683878
- -3.0 vs -0.9 NCT00528879
- -3.2 vs -1.0 NCT00528879
- -1.6 vs -0.7 NCT00680745
- -1.7 vs -0.8 NCT00680745
- 0.1 vs 1.6 NCT00683878
- 0.3 vs 1.8 NCT00683878
- -2.2 vs -0.9 NCT00528879
- -2.4 vs -1.0 NCT00528879
- -1.2 vs -0.7 NCT00680745
- -1.2 vs -0.8 NCT00680745
- -2.1 vs -0.3 NCT00984867
- -2.6 vs -1.3 NCT00643851
- -2.9 vs -1.5 NCT00643851
- -2.7 vs -1.3 NCT00643851
- -3.0 vs -1.5 NCT00643851
- -3.3 vs -1.4 NCT00859898
- -2.7 vs -1.4 NCT00859898
- -3.2 vs 1.4 NCT00660907
- -2.4 vs 1.3 NCT02564926
HbA1c below 7%
- Bexagliflozin
- —Not reported
- Dapagliflozin
- 50.8% vs 31.6%+19.2 vs placeboNCT00528372
17 other results
- 51.6% vs 31.6% NCT00528372
- 31.8% vs 11.1% NCT01392677
- 44.2% vs 31.6% NCT00528372
- 44% vs 31.6% NCT00528372
- 41.3% vs 31.6% NCT00528372
- 51.4% vs 31.6% NCT00528372
- 40.6% vs 25.9% NCT00528879
- 31.7% vs 13% NCT00680745
- 38.8% vs 22.4% NCT00683878
- 37.5% vs 25.9% NCT00528879
- 30.3% vs 13% NCT00680745
- 32.5% vs 22.4% NCT00683878
- 33% vs 25.9% NCT00528879
- 26.8% vs 13% NCT00680745
- 26.6% vs 10% NCT03199053
- 22.5% vs 34.6% NCT00643851
- 52.4% vs 34.6% NCT00643851
Fasting plasma glucose, change
- Bexagliflozin
- -2.5 vs -1.2−1.3 vs placeboNCT03259789
10 other results
- -1.8 vs -1.4 NCT03115112
- -1.2 vs -0.1 NCT02390050
- -1.0 vs 0.1 NCT02390050
- -1.1 vs -0.1 NCT02390050
- -1.2 vs -0.1 NCT02390050
- -1.1 vs 0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -0.8 vs 0.1 NCT02390050
- -0.6 vs -0.1 NCT02390050
- Dapagliflozin
- -1.3 vs 0.2−1.5 vs placeboNCT00984867
34 other results
- -1.6 vs -0.2 NCT00528372
- -1.6 vs -0.2 NCT00528372
- -1.9 vs -0.0 NCT01392677
- -1.2 vs 0.2 NCT00673231
- -1.0 vs 0.2 NCT00673231
- 0.1 vs 1.0 NCT00357370
- -0.9 vs -0.1 NCT00528372
- -0.7 vs 0.2 NCT00673231
- -1.1 vs -0.1 NCT00528372
- -0.5 vs 1.0 NCT00357370
- -1.3 vs -0.2 NCT00528372
- -1.5 vs -0.2 NCT00528372
- -0.9 vs -0.1 NCT00528372
- -1.0 vs -0.1 NCT00528372
- -0.8 vs -0.2 NCT00528372
- -1.4 vs -0.2 NCT00528372
- -0.2 vs -0.1 NCT00528372
- -1.6 vs -0.1 NCT00680745
- -0.8 vs -0.1 NCT00528372
- -1.3 vs -0.3 NCT00528879
- -1.6 vs -0.3 NCT00683878
- -0.9 vs 0.1 NCT00528879
- -1.2 vs -0.3 NCT00528879
- -1.2 vs -0.1 NCT00680745
- -1.4 vs -0.3 NCT00683878
- -0.7 vs 0.1 NCT00528879
- -1.0 vs -0.3 NCT00528879
- -0.9 vs -0.1 NCT00680745
- -0.3 vs 0.1 NCT00528879
- -0.6 vs 0.5 NCT03199053
- -2.3 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00859898
- -2.6 vs -1.9 NCT00859898
3-point MACE (% with event)
- Bexagliflozin
- —Not reported
- Dapagliflozin
- —Not posted · NCT04170998
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Bexagliflozin: 7 of 7 rows · Dapagliflozin: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bexagliflozin Rows use multiple source trials | Dapagliflozin Rows use multiple source trials |
|---|---|---|
| HbA1c 7.0 or Less event count · % of participants | 0.26% (n=158) vs 0.06% (n=159) placebo @ 12wk20 mga,b,c NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 3 other source trials22.2% (n=72) vs 15.3% (n=72) placebo @ 12wk*10 mg NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted 36% (n=75) vs 15.3% (n=72) placebo @ 12wk*20 mg NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted 21.1% (n=71) vs 15.3% (n=72) placebo @ 12wk*5 mg NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted | 13% (n=23) vs 5.3% (n=19) placebo @ 12wk*10 mgd,a,b,c NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted show 1 more dose4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted |
| SBP absolute change · mmHg | -5.03 vs 2.04 placebo mmHg @ 24wk20 mge,f,c,g NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 2 other source trials-4.23 vs -1.9 Sitagliptin mmHg @ 24wk NCT03115112 · Phase 3 -10.14 vs -7.51 placebo mmHg @ 24wk20 mg NCT02836873 · Phase 3 | -2.18 vs 4.63 Glimepiride mmHg @ 52wke,f,c,g NCT02564926 · Phase 4 · registry result, not featured evidence |
| Seated SBP absolute change · mmHg | -13.48 vs -6.95 Glimepiride mmHg @ 60wkf,h,i NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | -4.04 vs -0.27 placebo mmHg @ 8wk10 mgf,h,i NCT01392677 · Phase 3 · combination 1 other source trial-5.98 vs -5.12 placebo mmHg @ 8wk NCT00984867 · Phase 3 |
| Dropout rate | 3.9%20 mgj NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results15.5% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.8%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 11.4%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.3% NCT03115112 · Phase 3 3.2%20 mg NCT02836873 · Phase 3 9.2%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 6.9%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | 18.6%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results14.5%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.8%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.8%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 16.2%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.7%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 13.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 0%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 14.2%Dapagliflozin NCT00859898 · Phase 3 13.3%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 16.3%5 mg NCT00643851 · Phase 3 8.8%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 11.9%10 mg NCT00528879 · Phase 3 · combination 10.9%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 12.4%2.5 mg NCT00528879 · Phase 3 · combination 20.7% NCT00660907 · Phase 3 · combination 6.6%10 mg NCT00680745 · Phase 3 · combination 9%5 mg NCT00680745 · Phase 3 · combination 9.1%2.5 mg NCT00680745 · Phase 3 · combination 7.3%10 mg NCT01392677 · Phase 3 · combination 10%10MG NCT00683878 · Phase 3 · combination 11.3%5MG NCT00683878 · Phase 3 · combination 7.6% NCT00984867 · Phase 3 9.2%10mg NCT00673231 · Phase 3 12.3%5mg NCT00673231 · Phase 3 10.9%2.5mg NCT00673231 · Phase 3 2.5%10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 6.2%Dapagliflozin NCT03199053 · Phase 3 · background therapy 1.3%10 mg NCT01730534 · Phase 3 16.7%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 16.7%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination 12.9% NCT03782259 · Phase 4 · registry result, not featured evidence 16% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence 7.4%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 7.7% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence 8.3% NCT03074630 · Phase 4 · registry result, not featured evidence 13.3% NCT02564926 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%20 mgj NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results1.4% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 —20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.6% NCT03115112 · Phase 3 0.6%20 mg NCT02836873 · Phase 3 —20 mg NCT02390050 · Phase 2 · registry result, not featured evidence —10 mg NCT02390050 · Phase 2 · registry result, not featured evidence —5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | 8.6%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 4.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 —20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.1%Dapagliflozin NCT00859898 · Phase 3 1.9%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 3%5 mg NCT00643851 · Phase 3 1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 3%10 mg NCT00528879 · Phase 3 · combination 1.5%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 2.9%2.5 mg NCT00528879 · Phase 3 · combination 8.1% NCT00660907 · Phase 3 · combination 2%10 mg NCT00680745 · Phase 3 · combination 2.1%5 mg NCT00680745 · Phase 3 · combination 3.2%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 2.1%10MG NCT00683878 · Phase 3 · combination 2.1%5MG NCT00683878 · Phase 3 · combination 3.1% NCT00984867 · Phase 3 3.1%10mg NCT00673231 · Phase 3 4.2%5mg NCT00673231 · Phase 3 2.5%2.5mg NCT00673231 · Phase 3 —10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy —10 mg NCT01730534 · Phase 3 —Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence —T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence —Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence —Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 4% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence —10 mg NCT03387683 · Phase 4 · registry result, not featured evidence — NCT02433678 · Phase 4 · registry result, not featured evidence —10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence — NCT02564926 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 33%20 mgj NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 0.7%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.7% NCT03115112 · Phase 3 7%20 mg NCT02836873 · Phase 3 2.6%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 4.2%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence 0%Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | 1.4%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 7.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.2%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 2.3%Dapagliflozin NCT00859898 · Phase 3 1.4%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 4.4%5 mg NCT00643851 · Phase 3 3.1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 10.4%10 mg NCT00528879 · Phase 3 · combination —5 mg NCT00528879 · Phase 3 · combination 6.6%5.0 mg NCT00528879 · Phase 3 · combination 10.9%2.5 mg NCT00528879 · Phase 3 · combination 8.6% NCT00660907 · Phase 3 · combination 6%10 mg NCT00680745 · Phase 3 · combination 6.9%5 mg NCT00680745 · Phase 3 · combination 7.1%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 1.4%10MG NCT00683878 · Phase 3 · combination 2.8%5MG NCT00683878 · Phase 3 · combination 4.4% NCT00984867 · Phase 3 7.1%10mg NCT00673231 · Phase 3 4.7%5mg NCT00673231 · Phase 3 7.4%2.5mg NCT00673231 · Phase 3 5.6%10mg QD NCT02413398 · Phase 3 0%10 mg NCT03199053 · Phase 3 4.8%10 mg NCT03199053 · Phase 3 0%10 mg NCT03199053 · Phase 3 · combination 1.2%5 mg NCT03199053 · Phase 3 0%5 mg NCT03199053 · Phase 3 9.1%5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy 37.4%10 mg NCT01730534 · Phase 3 0%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 0% NCT02235298 · Phase 4 · registry result, not featured evidence 0% NCT02796170 · Phase 4 · registry result, not featured evidence 0%10mg NCT03338855 · Phase 4 · registry result, not featured evidence 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 0%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 0% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence 10% NCT02564926 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 20 mgj hypoglycaemia 42% (placebo 43.4%) urinary tract infection 11.3% (placebo 10.6%) upper respiratory tract infection 9.9% (placebo 9.3%) NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more resultshypoglycemia 16.9% nasopharyngitis 13.6% urinary tract infection 11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg nasopharyngitis 5.7% (placebo 8.2%) polydipsia 3.2% (placebo 2.5%) polyuria 3.2% (placebo 3.8%) NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 20 mg polyuria 7.2% (placebo 2.9%) urinary tract infection 5.1% (placebo 2.9%) abdominal pain 3.6% (placebo 7.2%) NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg hypoglycaemia 25.5% (placebo 25.8%) polyuria 7.6% (placebo 4.5%) nasopharyngitis 7% (placebo 8.4%) NCT02836873 · Phase 3 20 mg hypoglycemia 5.3% (placebo 1.4%) dysuria 3.9% (placebo 1.4%) nasopharyngitis 3.9% (placebo 4.2%) NCT02390050 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 5.6% (placebo 4.2%) pharyngitis 4.2% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT02390050 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 6.9% (placebo 4.2%) diarrhea 2.8% (placebo 2.8%) dizziness 2.8% (placebo 1.4%) NCT02390050 · Phase 2 · registry result, not featured evidence diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 6.3% gastrointestinal sounds abnormal 6.3% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination laceration 6.3% presyncope 6.3% diarrhea 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination dizziness 4.2% headache 4.2% nasal congestion 4.2% NCT02820298 · Phase 1 · registry result, not featured evidence chest discomfort 4.3% dizziness 4.3% headache 4.3% NCT02820298 · Phase 1 · registry result, not featured evidence | 10 mg AMk nasopharyngitis 14.3% (placebo 9.3%) arthralgia 8.6% (placebo 4%) headache 8.6% (placebo 12%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 42 more results10 mg PM headache 13.2% (placebo 12%) upper respiratory tract infection 11.8% (placebo 5.3%) back pain 9.2% (placebo 6.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg AM pharyngitis 9.4% (placebo 8%) arthralgia 7.8% (placebo 4%) headache 7.8% (placebo 12%) NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 5 mg PM headache 16.2% (placebo 12%) nasopharyngitis 13.2% (placebo 9.3%) arthralgia 11.8% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg AM nasopharyngitis 16.9% (placebo 9.3%) influenza 10.8% (placebo 4%) arthralgia 9.2% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg PM nasopharyngitis 16.4% (placebo 9.3%) abdominal pain 9% (placebo 2.7%) dizziness 9% (placebo 2.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg back pain 12.5% (placebo 8.7%) headache 12.5% (placebo 8.7%) fatigue 8.3% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 20 mg nausea 12.5% (placebo 4.3%) pollakiuria 12.5% (placebo 17.4%) vomiting 12.5% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 diarrhoea 7.1% vulvovaginal mycotic infection 3.3% urinary tract infection 2.8% NCT00859898 · Phase 3 · combination 5 mg dyslipidaemia 5.4% upper respiratory tract infection 4.9% urinary tract infection 4.4% NCT00643851 · Phase 3 10 mg back pain 13.3% (placebo 8%) influenza 12.6% (placebo 10.9%) diarrhoea 11.9% (placebo 7.3%) NCT00528879 · Phase 3 · combination 5.0 mg influenza 14.6% (placebo 10.9%) headache 9.5% (placebo 5.8%) arthralgia 7.3% (placebo 5.1%) NCT00528879 · Phase 3 · combination 2.5 mg influenza 13.9% (placebo 10.9%) nasopharyngitis 11.7% (placebo 8.8%) back pain 8% (placebo 8%) NCT00528879 · Phase 3 · combination 10 mg hypoglycemia 7.9% (placebo 4.8%) nasopharyngitis 3.3% (placebo 2.7%) hypertension 1.3% (placebo 4.1%) NCT00680745 · Phase 3 · combination 5 mg hypoglycemia 6.9% (placebo 4.8%) nasopharyngitis 5.5% (placebo 2.7%) hypertension 1.4% (placebo 4.1%) NCT00680745 · Phase 3 · combination 2.5 mg hypoglycemia 7.1% (placebo 4.8%) hypertension 5.2% (placebo 4.1%) nasopharyngitis 1.9% (placebo 2.7%) NCT00680745 · Phase 3 · combination 10MG dyslipidaemia 9.3% (placebo 4.3%) nasopharyngitis 7.9% (placebo 3.6%) diarrhoea 6.4% (placebo 4.3%) NCT00683878 · Phase 3 · combination 5MG upper respiratory tract infection 6.4% (placebo 5.8%) dyslipidaemia 5.7% (placebo 4.3%) nasopharyngitis 5% (placebo 3.6%) NCT00683878 · Phase 3 · combination nasopharyngitis 4% (placebo 6.2%) NCT00984867 · Phase 3 10mg hypoglycemia 44.9% (placebo 42.1%) nasopharyngitis 8.7% (placebo 11.2%) urinary tract infection 5.6% (placebo 3%) NCT00673231 · Phase 3 5mg hypoglycemia 47.6% (placebo 42.1%) nasopharyngitis 13.7% (placebo 11.2%) hypertension 6.1% (placebo 8.1%) NCT00673231 · Phase 3 2.5mg hypoglycemia 55% (placebo 42.1%) nasopharyngitis 13.9% (placebo 11.2%) hypertension 5.4% (placebo 8.1%) NCT00673231 · Phase 3 10 mg abdominal pain 4.8% (placebo 2.6%) abdominal pain upper 4.8% (placebo 0%) bronchitis 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg dysmenorrhoea 9.5% (placebo 2.6%) headache 9.5% (placebo 1.3%) conjunctivitis allergic 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg pharyngotonsillitis 14.3% (placebo 1.3%) tonsillitis 14.3% (placebo 0%) abdominal pain 0% (placebo 2.6%) NCT03199053 · Phase 3 · combination 5 mg headache 7.4% (placebo 1.3%) hypertriglyceridaemia 4.9% (placebo 1.3%) diarrhoea 3.7% (placebo 3.9%) NCT03199053 · Phase 3 5 mg headache 9.1% (placebo 1.3%) nasopharyngitis 3.6% (placebo 2.6%) anxiety 1.8% (placebo 0%) NCT03199053 · Phase 3 5 mg influenza 5.5% (placebo 2.6%) abdominal pain upper 3.6% (placebo 0%) headache 3.6% (placebo 1.3%) NCT03199053 · Phase 3 10 mg renal impairment 1.4% (placebo 1.7%) acute kidney injury 1% (placebo 1.3%) chronic kidney disease 0.9% (placebo 1.2%) NCT01730534 · Phase 3 genital mycotic infection 13.3% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence genital mycotic infection 26.7% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence transcient syncope 12.5% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence transcient syncope 0% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence nausea and vomiting 24% (placebo 0%) genital mycosis 0% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence nausea and vomiting 20% (placebo 0%) genital mycosis 8% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence · combination dysuria 12% (placebo 0%) frequency of urination 12% (placebo 0%) balanitis 2% (placebo 0%) NCT02235298 · Phase 4 · registry result, not featured evidence cold like symptoms 4.5% genital yeast infection 4.5% abrasion of left cornea 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 10mg Once Daily genital fungal infections 20.8% NCT02682563 · Phase 4 · registry result, not featured evidence nasopharyngitis 6.7% toothache 6.7% hypoglycaemia 5% NCT02564926 · Phase 4 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2/3 versus Phase 3.
- bPopulation context differs: baseline_threshold differs (bmi<=45 versus bmi<=45, hba1c<=10.5, hba1c>=7.5); prior_therapy differs (none recorded versus experienced).
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 3.
- fPopulation comparability has not been reviewed for both studies.
- gAssessment timepoints differ: 52 weeks versus 24 weeks.
- hTreatment context differs: combination versus monotherapy.
- iAssessment timepoints differ: 8 weeks versus 60 weeks.
- jPopulation comparability has not been reviewed for 13 of these studies.
- kPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 5 more results
show 1 more result
show 17 more results
show 8 more results
show 3 more results
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 2 more results
show 2 more results
+ 35 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Dapagliflozin's landscape